Lenka Hošková

Lenka Hošková

Auto-generated profile, based on publicly available information

Lenka Hošková

Klinika kardiologie Institut klinické a experimentální medicíny Praha Česká republika

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2017 in Physiological Research
Verified
Journal Article
Closed access
LHL. Hošková
L. Hošková
IMI. Málek
I. Málek
LKL. Kopkan
L. Kopkan
JKJ. Kautzner
J. Kautzner
Solid organ transplantation is an established treatment modality in patients with end-stage organ damage in cases where other therapeutic options fail. The long-term outcomes of solid organ transplant recipients have improved considerably since the introduction of the first calcineurin inhibitor (CNI) - cyclosporine. In 1984, the potent immunosuppressive properties of another CNI, tacrolimus, were discovered. The immunosuppressive effects of CNIs result from the inhibition of interleukin-2 synthesis and reduced proliferation of T cells due to calcineurin blockade. The considerable side effects that are associated with CNIs therapy include arterial hypertension and nephrotoxicity. The focus of this article was to review the available literature on the pathophysiological mechanisms of CNIs that induce chronic nephrotoxicity and arterial hypertension. CNIs lead to activation of the major vasoconstriction systems, such as the renin-angiotensin and endothelin systems, and increase sympathetic nerve activity. On the other hand, CNIs are known to inhibit NO synthesis and NO-mediated vasodilation and to increase free radical formation. Altogether, these processes cause endothelial dysfunction and contribute to the impairment of organ function. A better insight into the mechanisms underlying CNI nephrotoxicity could assist in developing more targeted therapies of arterial hypertension or preventing CNI nephrotoxicity in organ transplant recipients, including heart transplantation.

1 October 2006 in European Journal of Heart Failure
Verified
Journal Article
Closed access
LRLucie Riedlbauchová
Lucie Riedlbauchová
RĈRobert Ĉihaák
Robert Ĉihaák
JBJan Byteŝník
Jan Byteŝník
VVVlastimil Vanĉura
Vlastimil Vanĉura
PFPetr Frídl
Petr Frídl
JKJosef Kautzner
Josef Kautzner
Background: The benefit of biventricular pacing (BiV) may be substantially affected by optimal lead placement. Aim: To evaluate the importance of right ventricular (RV) lead positioning on clinical outcome of BiV. Methods and results: A total of 99 patients with symptomatic heart failure and implantation of BiV system were included. Position of the left-ventricular (LV) lead was selected based on timing of local endocardial signal within the terminal portion of the QRS complex. RV lead was preferably positioned at the midseptum (n = 74, RVS group) where the earliest RV endocardial signal was recorded. A subgroup of patients had RV lead placed in the apex (n = 25, RVA group). NYHA class, maximum oxygen-uptake (VO2max), LV end-diastolic diameter (LVEDD, mm) and ejection fraction were assessed every third month. A trend towards greater improvement in NYHA class and significant increase in VO2max was present in the RVS group. Moreover, a significant decrease in LVEDD (ΔLVEDD) was observed in the RVS group only (− 3.4 ± 6.5 mm versus + 1.7 ± 6.4 mm in RVA group at 12 months, p = 0.004). No significant correlation between the degree of ΔLVEDD and QRS narrowing induced by BiV was found. LVEDD reduction was predominantly present in dilated cardiomyopathy. Conclusions: Midseptal positioning of the RV lead appears to promote reverse LV remodelling during cardiac resynchronisation therapy.

10 April 2014 in Hypertension Research
Verified
Journal Article
Closed access
LHLenka Hošková
Lenka Hošková
IMIvan Málek
Ivan Málek
JKJosef Kautzner
Josef Kautzner
EHEva Honsová
Eva Honsová
RDRichard P E van Dokkum
Richard P E van Dokkum
LKLibor Kopkan
Libor Kopkan

26 May 2016 in Annals of Transplantation
Verified
Journal Article
Closed access
PDF file
LHLenka Hošková
Lenka Hošková
JFJanka Franeková
Janka Franeková
IMIvan Málek
Ivan Málek
JKJosef Kautzner
Josef Kautzner
OSOndřej Szárszoi
Ondřej Szárszoi
VMVojtěch Melenovský
Vojtěch Melenovský
BACKGROUND Acute kidney injury (AKI) is a risk factor for adverse hospital outcomes in recipients of a heart transplantation (HTx). Timely recognition of AKI is crucial for the initiation of proper treatment. We hypothesized that serum or urine biomarkers can predict AKI. MATERIAL AND METHODS In this prospective study we evaluated 117 consecutive patients after HTx. AKI was defined as an increase of the serum creatinine level by ≥50% or a worsening of the renal function requiring renal replacement therapy during the first post-HTx week. We serially sampled serum cystatin C (S-cystatin C) as a marker of glomerular filtration and urinary neutrophil gelatinase-associated lipocalin (U-NGAL) as a marker of tubular damage. RESULTS A cohort of 30 patients (25.6%) fulfilled the criteria of AKI. S-cystatin C allowed the earliest separation between the AKI and non-AKI groups, with a significant difference present as soon as 3 h after surgery and it persisted on days 7, 10, and 30. The increase in S-cystatin C preceded the serum creatinine elevation by 4 days. In a multivariate analysis, S-cystatin C >1.6 mg/L at 3 h after HTx predicted AKI with OR 4.3 (95% CI: 1.6-11.5). U-NGAL was significantly higher at day 3 in the AKI group (p=0.003) and elevated S-cystatin C (≥2.54 mg/L on day 7) could predict 1-year mortality in these HTx recipients. CONCLUSIONS Our study showed that the measurement of S-cystatin C at 3 h after surgery may help to identify patients with high risk for renal complications. A persistent elevation of S-cystatin C also predicts 1-year mortality.

3 December 2015 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
ZSZuzana Secnikova
Zuzana Secnikova
DGDana Gopfertova
Dana Gopfertova
LHLenka Hoskovac
Lenka Hoskovac
JHJana Hercogova
Jana Hercogova
MDMartina Dzambova
Martina Dzambova
ZSZdenek Smerhovsky
Zdenek Smerhovsky
To perform the first study in Czech Republic on heart transplant recipients (HTRs), compare the risks for different types of cancer and provide comprehensive analysis of skin cancer and other types of cancer morbidity from which we would be able to derive an evidence-based skin cancer surveillance program. A retrospective cohort study was performed to determine and compare standardized morbidity ratio (SMR) of different types of cancer developed after heart transplantation. We analysed data obtained from medical documentation of 603 HTRs transplanted between 1993 and 2010. 191 incident cases of malignancy occurred in123 HTRs (20.4%). According to expectations, nonmelanoma skin cancer was the most frequent type of malignancy (119 cases) with SMR 7.6 (P < 0.001), followed by lung cancer with SMR 2.7 (P < 0.001). SMR for melanoma was 2.5, P = 0.129. Other types of cancer in HTRs (prostate and kidney cancer) were less frequent (SMR 2.06, P = 0.038 and SMR 2.03, P = 0.122). The risk of malignancy development is significantly higher for HTRs compared to the general population. Squamous cell carcinoma of the skin is the most frequent type of cancer followed by basal cell carcinoma. These findings emphasise the importance of regular skin cancer screening in HTRs.

9 December 2016 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
JFJanka Franeková
Janka Franeková
PSPeter Sečník
Peter Sečník
PLPetra Lavríková
Petra Lavríková
ZKZdenek Kubíček
Zdenek Kubíček
LHLenka Hošková
Lenka Hošková
AJAntonín Jabor
Antonín Jabor